May 12, 2020
Ulcerative Colitis Market Report 2020: Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares through 2016-2024
Apr 09, 2020
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis
Feb 25, 2020
InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal
Oct 17, 2019
Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics
Apr 04, 2019
Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases
Jan 07, 2019
Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis
Nov 27, 2018
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
Oct 22, 2018
Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis
Oct 22, 2018
Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week
Oct 12, 2018
First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)
Aug 06, 2018
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis
Apr 12, 2018
InDex Pharmaceuticals Announces the Agenda for its Capital Markets Day in Stockholm on April 25, 2018
Mar 26, 2018
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
Mar 19, 2018
Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
Oct 12, 2017
InDex Pharmaceuticals Gets New Patent in the U.S.
Aug 09, 2017
InDex Pharmaceuticals Receives Orphan-drug Designation for Pediatric Ulcerative Colitis in the US
Aug 03, 2017
Ulcerative Colitis Therapeutics Pipeline Analysis 2017: Approximately 89 Drug Candidates in Different Stages of Development